The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.